Abstract |
This study analyzed whether platelet amyloid beta-protein precursor (AbetaPP) isoform ratio correlates with cognition or cognitive decline in patients with Alzheimer's disease (AD). Platelet AbetaPP isoform ratio was measured, and cognitive assessment was performed using the Mini-Mental State Examination (MMSE) in 66 AD patients at baseline (T0) and in 29 of these patients in a one-year follow-up (T1). There was a significant correlation between the AbetaPP isoform ratios and MMSE scores in the 66 AD patients at T0. The T1 subjects were divided into two groups: 12 "no decliners" (MMSE score, T1-T0 > or = 0) and 17 "decliners" (MMSE score, T1-T0 < 0). The decliners group showed a significantly greater reduction of AbetaPP isoform ratio from T0 to T1 than the no decliners group. However, the decline of the ratio did not correlate with the decline of MMSE score. These findings indicate that AbetaPP isoform ratio correlates with cognition, and reduction in this ratio may be a marker for cognitive decline in AD patients.
|
Authors | Hsiu-Chih Liu, Hsiao-Chien Wang, Shun-Yao Ko, Pei-Ning Wang, Chin-Wen Chi, Chen-Jee Hong, Ker-Neng Lin, Tsung-Yun Liu |
Journal | Journal of Alzheimer's disease : JAD
(J Alzheimers Dis)
Vol. 11
Issue 1
Pg. 77-84
(Mar 2007)
ISSN: 1387-2877 [Print] Netherlands |
PMID | 17361037
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amyloid beta-Protein Precursor
- Biomarkers
- Cholinesterase Inhibitors
- Protein Isoforms
|
Topics |
- Aged
- Aged, 80 and over
- Alzheimer Disease
(blood, diagnosis, drug therapy)
- Amyloid beta-Protein Precursor
(blood)
- Biomarkers
(blood)
- Blood Platelets
(metabolism)
- Cholinesterase Inhibitors
(therapeutic use)
- Cognition Disorders
(blood, diagnosis, drug therapy)
- Cohort Studies
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Male
- Mental Status Schedule
- Protein Isoforms
(genetics)
- Reference Values
|